Contact
searchSearch
HMP Global
Login

News

News
Long-Term Real-World Efficacy of CPX-351 Therapy for Patients With High-Risk AML
04/09/2025
Emily Estrada
In a long-term, real-world analysis, CPX-351 induction therapy was significantly associated with achievement of measurable residual disease status, which was correlated with improved overall survival among patients with high-risk AML.
In a long-term, real-world analysis, CPX-351 induction therapy was significantly associated with achievement of measurable residual disease status, which was correlated with improved overall survival among patients with high-risk AML.
In a long-term, real-world...
04/09/2025
Oncology
News
Chidamide and CAG Plus Venetoclax-Azacitidine Regimen Demonstrates High Response Rates in Older Patients With Acute Myeloid Leukemia
04/04/2025
Emily Estrada
An induction therapy regimen of chidamide with cytarabine, aclarubicin, and G‐CSF (CAG) plus venetoclax-azacitidine for the treatment of acute myeloid leukemia showed efficacy and tolerability in a phase 2 trial.
An induction therapy regimen of chidamide with cytarabine, aclarubicin, and G‐CSF (CAG) plus venetoclax-azacitidine for the treatment of acute myeloid leukemia showed efficacy and tolerability in a phase 2 trial.
An induction therapy regimen of...
04/04/2025
Oncology
News
ITGB7, SCD, and CD69 Expression Correlated With Overall Survival in Acute Myeloid Leukemia
04/03/2025
Emily Estrada
Researchers identified higher expression of CD69, ITBG7, SCD genes as prognostic indicators of disease and survival in a retrospective analysis.
Researchers identified higher expression of CD69, ITBG7, SCD genes as prognostic indicators of disease and survival in a retrospective analysis.
Researchers identified higher...
04/03/2025
Oncology
News
Outcomes of Frontline Treatment Regimens for Patients With FLT3-Mutated AML
04/03/2025
Emily Estrada
FLT3 inhibitors and allogeneic stem cell transplantation were associated with improved survival outcomes for patients diagnosed with FLT3-mutated acute myeloid leukemia, according to a retrospective study.
FLT3 inhibitors and allogeneic stem cell transplantation were associated with improved survival outcomes for patients diagnosed with FLT3-mutated acute myeloid leukemia, according to a retrospective study.
FLT3 inhibitors and allogeneic...
04/03/2025
Oncology
News
Venetoclax and Hypomethylating Agent Treatment Shows Efficacy for R/R Acute Myeloid Leukemia, With Genetic Predictors of Response Identified
02/28/2025
Emily Estrada
Venetoclax plus hypomethylating agents demonstrated efficacy for treating R/R AML, with genetic features, including distinct mutations, predicting response to treatment, according to a retrospective study.
Venetoclax plus hypomethylating agents demonstrated efficacy for treating R/R AML, with genetic features, including distinct mutations, predicting response to treatment, according to a retrospective study.
Venetoclax plus hypomethylating...
02/28/2025
Oncology
News
Autologous Hematopoietic Stem Cell Transplantation as Additional Treatment Option for Secondary Acute Myeloid Leukemia
02/28/2025
Emily Estrada
While allogeneic hematopoietic stem cell transplantation is the standard treatment for secondary AML, autologous hematopoietic stem cell transplantation shows promising outcomes as an additional treatment option, according to a retrospective...
While allogeneic hematopoietic stem cell transplantation is the standard treatment for secondary AML, autologous hematopoietic stem cell transplantation shows promising outcomes as an additional treatment option, according to a retrospective...
While allogeneic hematopoietic...
02/28/2025
Oncology
FDA Approval
FDA Approves Treosulfan With Fludarabine for Patients With AML or MDS Prior to AlloHSCT
02/07/2025
Emily Estrada
On January 21, 2025, the FDA approved treosulfan with fludarabine prior to allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome.
On January 21, 2025, the FDA approved treosulfan with fludarabine prior to allogeneic hematopoietic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome.
On January 21, 2025, the FDA...
02/07/2025
Oncology
News
Midostaurin Plus CLAG-M Yields Comparable Results to Midostaurin Plus 7+3 Therapy, High Remission Rates Among Patients With FLT3-Mutated AML
01/31/2025
Emily Estrada
For patients with AML and FLT3 mutation, treatment with midostaurin combined with cladribine, high-dose cytarabine, GCSF, and mitoxantrone is as safe and effective as midostaurin combined with standard therapy, according to a retrospective...
For patients with AML and FLT3 mutation, treatment with midostaurin combined with cladribine, high-dose cytarabine, GCSF, and mitoxantrone is as safe and effective as midostaurin combined with standard therapy, according to a retrospective...
For patients with AML and FLT3...
01/31/2025
Oncology
News
Venetoclax Plus Hypomethylating Agents Demonstrated Improved Outcomes and Infection Risk Among Older Patients With Acute Myeloid Leukemia
01/31/2025
Emily Estrada
Venetoclax combined with hypomethylating agents for the treatment of acute myeloid leukemia improved infection rates and outcomes among patients, as compared to other chemotherapies, according to a retrospective analysis.
Venetoclax combined with hypomethylating agents for the treatment of acute myeloid leukemia improved infection rates and outcomes among patients, as compared to other chemotherapies, according to a retrospective analysis.
Venetoclax combined with...
01/31/2025
Oncology
News
Relationship Between BCL-2 Expression and Venetoclax Concentration Among Patients With AML
01/24/2025
Emily Estrada
Higher levels of BCL-2 expression at time of diagnosis may be associated with worse outcomes while higher blood concentrations of venetoclax may have an impact on timing of adverse reactions among patients with AML, according to a recent...
Higher levels of BCL-2 expression at time of diagnosis may be associated with worse outcomes while higher blood concentrations of venetoclax may have an impact on timing of adverse reactions among patients with AML, according to a recent...
Higher levels of BCL-2...
01/24/2025
Oncology

Recent News

FDA Approval
FDA Approves Penpulimab for Patients With Non-Keratinizing Nasopharyngeal Carcinoma
04/24/2025
Stephanie Holland
On April 23, 2025, the FDA has approved penpulimab plus chemotherapy for patients with metastatic non-keratinizing nasopharyngeal carcinoma.
On April 23, 2025, the FDA has approved penpulimab plus chemotherapy for patients with metastatic non-keratinizing nasopharyngeal carcinoma.
On April 23, 2025, the FDA has...
04/24/2025
Oncology
News
Lenvatinib-Based Regimens Demonstrate Efficacy, Safety Among Pre-Treated Patients With Metastatic Renal Cell Carcinoma
04/24/2025
Stephanie Holland
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma.
According to retrospective results from the LENVA-LAT study, treatment with lenvatinib-based regimens demonstrated efficacy and safety among pre-treated patients with metastatic renal cell carcinoma.
According to retrospective...
04/24/2025
Oncology
News
Palbociclib Plus Endocrine Therapy May Prolong Progression-Free Survival for Premenopausal Patients With HR-Positive, HER2-Negative Breast Cancer
04/23/2025
Stephanie Holland
According to extended follow-up results from the phase 2 Young-PEARL trial, palbociclib plus exemestane and ovarian function suppression prolonged progression-free survival among premenopausal patients with HR-positive, HER2-negative...
According to extended follow-up results from the phase 2 Young-PEARL trial, palbociclib plus exemestane and ovarian function suppression prolonged progression-free survival among premenopausal patients with HR-positive, HER2-negative...
According to extended follow-up...
04/23/2025
Oncology
News
Trastuzumab Rezetecan for Patients With HER2-Mutated Non-Small Cell Lung Cancer
04/22/2025
Stephanie Holland
According to results from the phase 2 HORIZON-Lung trial, trastuzumab rezetecan demonstrated promise among patients with HER2-mutated non-small cell lung cancer.
According to results from the phase 2 HORIZON-Lung trial, trastuzumab rezetecan demonstrated promise among patients with HER2-mutated non-small cell lung cancer.
According to results from the...
04/22/2025
Oncology
News
Temozolomide as Potential Second-Line Option for Patients With Small Cell Lung Cancer
04/21/2025
Stephanie Holland
According to results from a retrospective analysis of a real-world cohort, temozolomide showed potential as a second-line option for patients with small cell lung cancer.
According to results from a retrospective analysis of a real-world cohort, temozolomide showed potential as a second-line option for patients with small cell lung cancer.
According to results from a...
04/21/2025
Oncology
News
Adding Pembrolizumab to Docetaxel Does Not Improve Survival Outcomes for Metastatic Castration-Resistant Prostate Cancer
04/21/2025
Stephanie Holland
According to results from the phase 3 KEYNOTE-921 trial, the addition of pembrolizumab to docetaxel did not significantly improve survival outcomes among previously treated patients with metastatic castration-resistant prostate cancer.
According to results from the phase 3 KEYNOTE-921 trial, the addition of pembrolizumab to docetaxel did not significantly improve survival outcomes among previously treated patients with metastatic castration-resistant prostate cancer.
According to results from the...
04/21/2025
Oncology
News
Sacituzumab Govitecan Fails to Significantly Improve Survival in Advanced Urothelial Carcinoma
04/17/2025
Stephanie Holland
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis results from the phase 3 TROPICS-04 trial, sacituzumab govitecan did not significantly improve survival among previously treated patients with advanced urothelial carcinoma.
According to final analysis...
04/17/2025
Oncology
News
Rituximab Plus Lenalidomide Shows Durable Responses as Frontline Treatment for Patients With Follicular Lymphoma
04/16/2025
Emily Estrada
Rituximab plus lenalidomide demonstrates long-lasting responses and improved outcomes as first-line therapy for follicular lymphoma, according to a phase 2 trial.
Rituximab plus lenalidomide demonstrates long-lasting responses and improved outcomes as first-line therapy for follicular lymphoma, according to a phase 2 trial.
Rituximab plus lenalidomide...
04/16/2025
Oncology
News
Tegafur-Uracil Maintenance Did Not Improve Survival for Patients With Locally Advanced Cervical Cancer
04/15/2025
Stephanie Holland
According to results from the phase 3 GOTIC-002 trial, low-dose tegafur-uracil maintenance therapy did not improve survival among patients with locally advanced cervical cancer.
According to results from the phase 3 GOTIC-002 trial, low-dose tegafur-uracil maintenance therapy did not improve survival among patients with locally advanced cervical cancer.
According to results from the...
04/15/2025
Oncology
News
First-Line Durvalumab Plus Platinum-Etoposide for Patients With Extensive-Stage Small Cell Lung Cancer
04/14/2025
Stephanie Holland
According to final efficacy and safety results from the phase 3b LUMINANCE trial, first-line durvalumab plus platinum-etoposide demonstrated promise among patients with extensive-stage small cell lung cancer.
According to final efficacy and safety results from the phase 3b LUMINANCE trial, first-line durvalumab plus platinum-etoposide demonstrated promise among patients with extensive-stage small cell lung cancer.
According to final efficacy and...
04/14/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use